TrialLancet (London, England)2025

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.

Fatoumata Diallo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.